Remission of generalized anxiety disorder: A review of the paroxetine clinical trials database

Journal of Clinical Psychiatry

Volumn 67, Issue 1, 2006, Pages 41-47

  Rickels, Karl ^a   Rynn, Moira ^a   Iyengar, Malini ^b   Duff, David ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; DELORAZEPAM; DIAZEPAM; IMIPRAMINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AGED; ANXIETY; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; EJACULATION DISORDER; FEMALE; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; INSOMNIA; LONG TERM CARE; MALE; META ANALYSIS; MOOD DISORDER; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; SOMNOLENCE; SWEATING; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TRANQUILIZING ACTIVITY; WEIGHT GAIN; XEROSTOMIA;

EID: 32244442982     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0107     Document Type: Review

References (40)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition. Washington, DC: American Psychiatric Press; 1980
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Press; 1994
3. Rickets K, Rynn MA. What is generalized anxiety disorder? J Clin Psychiatry 2001;62(suppl 11):4-12
4. Lydiard RB. An overview of generalized anxiety disorder: disease state-appropriate therapy. Clin Ther 2000;22(suppl A):A3-A19
5. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
6. Wittchen HU, Zhao S, Kessler RC, et al. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:355-364
7. Carter RM, Wittchen HU, Pfister H, et al. One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depress Anxiety 2001;13:78-88
8. Greenberg PE, Sisitsky T, Kessler RC, et al. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry 1999;60:427-435
9. Bland RC, Newman SC, Orn H. Help-seeking for psychiatric disorders. Can J Psychiatry 1997;42:935-942
10. Weiller E, Bisserbe JC, Maier W, et al. Prevalence and recognition of anxiety syndromes in five European primary care settings: a report from the WHO study on psychological problems in general health care. Br J Psychiatry Suppl 1998;173:18-23
11. Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993;50:884-895
12. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993;328:1398-1405
13. Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry 1988;49:293-301
14. Rickels K, Case WG, Downing RW, et al. Long-term diazepam therapy and clinical outcome. JAMA 1983;250:767-771
15. Chouinard G, Goodman W, Greist J, et al. Results of a double-blind placebo-controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull 1990;26:279-284
16. Davidson JRT. Pharmacotherapy of posttraumatic stress disorder: treatment options, long-term follow-up, and predictors of outcome. J Clin Psychiatry 2000;61(suppl 5):52-56
17. Davidson JRT. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2001;62(suppl 11):46-50
18. Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997;95:153-160
19. Van Ameringen M, Mancini C, Streiner DL. Fluoxetine efficacy in social phobia. J Clin Psychiatry 1993;54:27-32
20. Rocca P, Fonzo V, Scotta M, et al. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 1997;95:444-450
21. Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 2000; 283:3082-3088
22. Pollack MH. Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission. J Clin Psychiatry 2001;62(suppl 19):20-25
23. Rickels K, Pollack MH, Sheehan DV, et al. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000;157:968-974
24. Rickels K, Zaninelli R, McCafferty J, et al. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2003;160:749-756
25. Stocchi F, Nordera G, Jokinen RH, et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 2003;64:250-258
26. Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001;62:350-357. Correction 2001;62:658
27. Hewett K, Adams A, Bryson H, et al. Generalised anxiety disorder: efficacy of paroxetine. Presented at the 7th World Congress of Biological Psychiatry; July 1-6, 2001; Berlin, Germany
28. Sheehan DV. Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data. J Clin Psychiatry 2001; 62(suppl 19):26-31
29. Leon AC, Olfson M, Portera L, et al. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med 1997;27:93-105
30. Ballenger JC. Remission rates in patients with anxiety disorders treated with paroxetine. J Clin Psychiatry 2004;65:1696-1707
31. Ballenger JC, Davidson JRT, Lecrubier Y, et al. International Consensus Group on Depression and Anxiety. A proposed algorithm for improved recognition and treatment of the depression/anxiety spectrum in primary care. Prim Care Companion J Clin Psychiatry 2001;3:44-52
32. Ballenger JC. Translational implications of the amygdala-stria terminalis model for the clinical anxiety disorders. Biol Psychiatry 1998;44: 1204-1207
33. Ballenger JC. Comorbidity of panic and depression: implications for clinical management. Int Clin Psychopharmacol 1998;13(suppl 4): S13-S17
34. Marshall RD, Beebe KL, Oldham M, et al. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 2001;158:1982-1988
35. Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993;8:189-195
36. Zohar J, Judge R, and the OCD Paroxetine Study Investigators. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry 1996;169:468-474
37. Baldwin D, Bobes J, Stein DJ, et al. Paroxetine in social phobia/social anxiety disorder, randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry 1999;175:120-126
38. Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 2001;179:15-22
39. Gorman JM. Treatment of generalized anxiety disorder. J Clin Psychiatry 2002;63(suppl 8):17-23
40. Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 2001;62(suppl 11):53-58